Showing results (191-200 of 254) with videos related to
Sort By:
Pageof 26
Leukemia|May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysisMeletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.Blood|July 16, 2008
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseaseMary E D Flowers, Jane F Apperley, Koen van Besien, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.British Journal of Haematology|February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyHang Quach, Liam Fernyhough, Ross Henderson, et al.Annals of Hematology|March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapyChan Y Cheah, Michael Dickinson, Michael S Hofman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.AIDS (London, England)|March 17, 2017
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapyTalia M Mota, Thomas A Rasmussen, Ajantha Rhodes, et al.Proceedings of the National Academy of Sciences of the United States of America|December 21, 2005
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in miceJennifer A Westwood, Mark J Smyth, Michele W L Teng, et al.The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.Pageof 26